Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management of the potential pediatric organ donor

Harish Vyas, DM, FRCP, FRCPCH
Thomas A Nakagawa, MD, FAAP, FCCM
Section Editor
George B Mallory, MD
Deputy Editor
Alison G Hoppin, MD


The management of potential donors is as complex as that of any other patient cared for in an intensive care unit (ICU). A major paradigm shift in strategy occurs after neurologic death. The goal of antemortem management is to maintain cerebral perfusion pressure, while the postmortem goal is to maintain the perfusion of all potential donor organs (table 1). Following neurologic death, circulatory collapse occurs within hours if there is no medical intervention.

Optimal management of the potential organ donor is a continuum of care that requires coordination between the medical and nursing teams in the ICU and the organ procurement organization (OPO). This allows for early identification of potential donors, timely determination of neurologic death, donation discussions with the family that are appropriately timed and sensitive to the family's emotional needs, medical interventions to preserve organ function, evaluation to determine donor potential and suitability, and recovery and placement of organs. The goals of this coordinated approach are to preserve the option of donation, enhance the likelihood of donation and organ recovery, and also to support grieving families with issues and decisions surrounding end-of-life care.

The process and timing of organ recovery is a complex task. In the absence of pediatric support, every effort should be made to transfer the child to a local pediatric critical care unit. If this is not possible due to patient instability, the local pediatric critical care unit should offer consultation or consider traveling to the referring unit to provide expertise in patient management. Organ recovery depends on the physiological stability of the donor. An unstable donor may require early organ recovery to avoid losing potential transplantable organs, whereas a stabilized donor with optimal management can be maintained for a longer period of time. In many instances, organizing appropriate laboratory and diagnostic testing, acceptance and placement of donor organs, coordination of organ recovery teams, and availability of an operating suite may require active medical management of the donor for 24 hours or longer. Prolonging the time interval between neurologic death and organ retrieval has not been associated with decreased organ procurement rates nor compromised quality of organ function [1,2].

The pathophysiology of neurologic death and management of the potential pediatric organ donor are discussed here. The determination of neurologic death and assessment of the pediatric patient for potential organ donation are discussed separately. (See "Diagnosis of brain death" and "Assessment of the pediatric patient for potential organ donation".)


Regardless of the initial cerebral insult, the end point of neurologic death is complete ischemia and irreversible loss of brainstem function. In some countries (eg, the United States) the term and medicolegal definitions focus on whole "brain death" (brain and brainstem), while in others (eg, the United Kingdom) the term and concept of "brainstem death" is used.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 6, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Inaba K, Branco BC, Lam L, et al. Organ donation and time to procurement: late is not too late. J Trauma 2010; 68:1362.
  2. Nijboer WN, Moers C, Leuvenink HG, Ploeg RJ. How important is the duration of the brain death period for the outcome in kidney transplantation? Transpl Int 2011; 24:14.
  3. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87:230.
  4. Novitzky D, Wicomb WN, Cooper DKC, et al. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant 1984; 4:63.
  5. Novitzky D. Haemodynamic change, myocardial injury and pulmonary oedema induced by sympathetic activity during the development of brain death in the baboon. Transplant Proc 1986; 18:609.
  6. Cooper DK, Novitzky D, Wicomb WN. The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. Ann R Coll Surg Engl 1989; 71:261.
  7. Pilati CF, Bosso FJ, Maron MB. Factors involved in left ventricular dysfunction after massive sympathetic activation. Am J Physiol 1992; 263:H784.
  8. White M, Wiechmann RJ, Roden RL, et al. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage. Circulation 1995; 92:2183.
  9. Owen VJ, Burton PB, Michel MC, et al. Myocardial dysfunction in donor hearts. A possible etiology. Circulation 1999; 99:2565.
  10. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996; 24:1352.
  11. Novitzky D, Wicomb WN, Rose AG, et al. Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. Ann Thorac Surg 1987; 43:288.
  12. Chen HI, Su CF, Chai CY. [Neural and hemodynamic mechanisms of neurogenic pulmonary edema]. Sheng Li Ke Xue Jin Zhan 1999; 30:203.
  14. Mallory GB Jr, Schecter MG, Elidemir O. Management of the pediatric organ donor to optimize lung donation. Pediatr Pulmonol 2009; 44:536.
  15. Finfer S, Bohn D, Colpitts D, et al. Intensive care management of paediatric organ donors and its effect on post-transplant organ function. Intensive Care Med 1996; 22:1424.
  16. Soifer B, Gelb AW. The multiple organ donor: identification and management. Ann Intern Med 1989; 110:814.
  17. Staworn D, Lewison L, Marks J, et al. Brain death in pediatric intensive care unit patients: incidence, primary diagnosis, and the clinical occurrence of Turner's triad. Crit Care Med 1994; 22:1301.
  18. Fiser DH, Jimenez JF, Wrape V, Woody R. Diabetes insipidus in children with brain death. Crit Care Med 1987; 15:551.
  19. Yoshioka T, Sugimoto H, Uenishi M, et al. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986; 18:565.
  20. Kinoshita Y, Yahata K, Yoshioka T, et al. Long-term renal preservation after brain death maintained with vasopressin and epinephrine. Transpl Int 1990; 3:15.
  21. Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004; 32:2318.
  22. Cooper DK, Basker M. Physiologic changes following brain death. Transplant Proc 1999; 31:1001.
  23. Masson F, Thicoïpe M, Latapie MJ, Maurette P. Thyroid function in brain-dead donors. Transpl Int 1990; 3:226.
  24. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482.
  25. Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med 2012; 40:1635.
  26. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation 1988; 45:32.
  27. Birks EJ, Burton PB, Owen VJ, et al. Molecular and cellular mechanisms of donor heart dysfunction. Transplant Proc 2001; 33:2749.
  28. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998; 65:1533.
  29. Ropper AH. Unusual spontaneous movements in brain-dead patients. Neurology 1984; 34:1089.
  30. Saposnik G, Bueri JA, Mauriño J, et al. Spontaneous and reflex movements in brain death. Neurology 2000; 54:221.
  31. Nakagawa TA. Updated pediatric donor management and dosing guidelines. NATCO, The Organization for Transplant Professionals, 2008. Available at: http://www.organdonationalliance.org/wp-content/uploads/toolbox/NATCOPedDonorManagementGuidelines-odt.pdf (Accessed on November 27, 2013).
  32. Malinoski DJ, Daly MC, Patel MS, et al. Achieving donor management goals before deceased donor procurement is associated with more organs transplanted per donor. J Trauma 2011; 71:990.
  33. Galbraith S, Quetschenbach J, Nakagawa TA. Maximizing Organ Recovery in Children when donor management goals are met. Presented at the 2013 National Pediatric Organ Donation Summit. Fort Worth, 2013.
  34. Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med 2015; 43:1291.
  35. Nelson K, Nakagawa TA, Berkowicz I. Organ donation in children. In: Rogers' textbook of pediatric intensive care, 5th ed, Nichols DG, Shaffner DH. (Eds), Wolters Kluwer, Philadelphia, PA 2015.
  36. Nakagawa TA. The process of organ donation and pediatric donor management. In: Textbook of critical care medicine, 5th ed, Fuhrman BP, Zimmerman JJ. (Eds), Elsevier Mosby, Philadelphia, PA 2015.
  37. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 2002; 106:836.
  38. Schnuelle P, Berger S, de Boer J, et al. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001; 72:455.
  39. Wahlers T, Cremer J, Fieguth HG, et al. Donor heart-related variables and early mortality after heart transplantation. J Heart Lung Transplant 1991; 10:22.
  40. Novitzky D, Wicomb WN, Cooper DK, et al. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg 1986; 41:520.
  41. Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med 1974; 291:707.
  42. Schnuelle P, Lorenz D, Mueller A, et al. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int 1999; 56:738.
  43. Ware LB, Fang X, Wang Y, et al. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung. J Appl Physiol (1985) 2002; 93:1869.
  44. Chamorro C, Silva JA, Romera MA. Cardiac donor management: another point of view. Transplant Proc 2003; 35:1935.
  45. Silva JA, Chamorro C, Romera MA. High doses of catecholamines in heart donor is not associated with early graft failure in recipient. Intensive Care Med 2002; 28:S66.
  46. Wheeldon DR, Potter CD, Oduro A, et al. Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995; 14:734.
  47. Hunt SA, Baldwin J, Baumgartner W, et al. Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med 1996; 24:1599.
  48. Stoica SC, Satchithananda DK, White PA, et al. Noradrenaline use in the human donor and relationship with load-independent right ventricular contractility. Transplantation 2004; 78:1193.
  49. Plurad DS, Bricker S, Neville A, et al. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. Am J Surg 2012; 204:856.
  50. Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001; 48:715.
  51. Powner DJ, Darby JM. Management of variations in blood pressure during care of organ donors. Prog Transplant 2000; 10:25.
  52. Shemie SD, Ross H, Pagliarello J, et al. Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ 2006; 174:S13.
  53. Gramm HJ, Zimmermann J, Meinhold H, et al. Hemodynamic responses to noxious stimuli in brain-dead organ donors. Intensive Care Med 1992; 18:493.
  54. Spittler JF, Wortmann D, von Düring M, Gehlen W. Phenomenological diversity of spinal reflexes in brain death. Eur J Neurol 2000; 7:315.
  55. Powner DJ, Allison TA. Cardiac dysrhythmias during donor care. Prog Transplant 2006; 16:74.
  56. Brembilla-Perrot B, Muhanna I, Nippert M, et al. Paradoxical effect of isoprenaline infusion. Europace 2005; 7:621.
  57. Phongsamran PV. Critical care pharmacy in donor management. Prog Transplant 2004; 14:105.
  58. Shafer TJ, Cosio C. Cardiopulmonary resuscitation of organ donors. Prog Transplant 2011; 21:351.
  59. Powner DJ, Delgado E. Using pressure-limited mechanical ventilation in caring for organ donors. Prog Transplant 2001; 11:174.
  60. Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. Prog Transplant 2004; 14:16.
  61. Recicar J, Niles P. Improving oxygenation when conventional ventilation fails: a case study. Prog Transplant 2002; 12:238.
  62. Sperber J, Lipcsey M, Larsson A, et al. Lung protective ventilation induces immunotolerance and nitric oxide metabolites in porcine experimental postoperative sepsis. PLoS One 2013; 8:e83182.
  63. Barber K, Falvey S, Hamilton C, et al. Potential for organ donation in the United Kingdom: audit of intensive care records. BMJ 2006; 332:1124.
  64. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85:278.
  65. Scheinkestel CD, Tuxen DV, Cooper DJ, Butt W. Medical management of the (potential) organ donor. Anaesth Intensive Care 1995; 23:51.
  66. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710.
  67. Powner DJ, Graham R. Airway pressure release ventilation during adult donor care. Prog Transplant 2010; 20:269.
  68. Hanna K, Seder CW, Weinberger JB, et al. Airway pressure release ventilation and successful lung donation. Arch Surg 2011; 146:325.
  69. Babcock WD, Menza RL, Riznyk S, et al. Results of a prospective study using high-frequency chest wall oscillation for organ donors. J Heart Lung Transplant 2002; 21:141.
  70. Kutsogiannis DJ, Pagliarello G, Doig C, et al. Medical management to optimize donor organ potential: review of the literature. Can J Anaesth 2006; 53:820.
  71. Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation 1993; 56:1418.
  72. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309:678.
  73. Young JB, Utter GH, Schermer CR, et al. Saline versus Plasma-Lyte A in initial resuscitation of trauma patients: a randomized trial. Ann Surg 2014; 259:255.
  74. Powner DJ, Crommett JW. Advanced assessment of hemodynamic parameters during donor care. Prog Transplant 2003; 13:249.
  75. Totsuka E, Dodson F, Urakami A, et al. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl Surg 1999; 5:421.
  76. Schneider A, Toledo-Pereyra LH, Zeichner WD, et al. Effect of dopamine and pitressin on kidneys procured and harvested for transplantation. Transplantation 1983; 36:110.
  77. Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet 1998; 352:1178.
  78. Katz K, Lawler J, Wax J, et al. Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation 2000; 47:33.
  79. Debelak L, Pollak R, Reckard C. Arginine vasopressin versus desmopressin for the treatment of diabetes insipidus in the brain dead organ donor. Transplant Proc 1990; 22:351.
  80. Holmquist M, Chabalewski F, Blount T, et al. A critical pathway: guiding care for organ donors. Crit Care Nurse 1999; 19:84.
  81. Benck U, Gottmann U, Hoeger S, et al. Donor desmopressin is associated with superior graft survival after kidney transplantation. Transplantation 2011; 92:1252.
  82. Nakagawa TA, Mou SS, American Transplant Coordinators Organization (NATCO). Management of the pediatric organ donor. In: The Clinician's Guide to Donation and Transplantation, Applied Measurement Professionals Inc, Lenexa, KS 2006.
  83. Masson F, Thicoipe M, Gin H, et al. The endocrine pancreas in brain-dead donors. A prospective study in 25 patients. Transplantation 1993; 56:363.
  84. United Network for Organ Sharing. Available at: www.unos.org (Accessed on September 14, 2007).
  85. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.
  86. Lugo N, Silver P, Nimkoff L, et al. Diagnosis and management algorithm of acute onset of central diabetes insipidus in critically ill children. J Pediatr Endocrinol Metab 1997; 10:633.
  87. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998; 17:423.
  88. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987; 43:852.
  89. Jeevanandam V, Todd B, Regillo T, et al. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994; 13:681.
  90. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001; 136:1377.
  91. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003; 75:1336.
  92. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2:761.
  93. Ranasinghe AM, Bonser RS. Endocrine changes in brain death and transplantation. Best Pract Res Clin Endocrinol Metab 2011; 25:799.
  94. Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. J Heart Lung Transplant 2009; 28:480.
  95. Nath DS, Ilias Basha H, Liu MH, et al. Increased recovery of thoracic organs after hormonal resuscitation therapy. J Heart Lung Transplant 2010; 29:594.
  96. Cherick WS, Edwards IB, Sweet SC, et al. The effect of hormonal resuscitation on organ utilization in pediatric donors, presented at the Pediatric Summit for Organ Donation and Transplantation. San Antonio; 2007.
  97. Robertson KM, Cook DR. Perioperative management of the multiorgan donor. Anesth Analg 1990; 70:546.
  98. Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68:1107.
  99. González-Segura C, Pascual M, García Huete L, et al. Donors with positive blood culture: could they transmit infections to the recipients? Transplant Proc 2005; 37:3664.
  100. Mirza D, Hastings M, Reyes J, et al. Organ donation from children with meningitis. Pediatr Infect Dis J 2003; 22:475.
  101. Satoi S, Bramhall SR, Solomon M, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001; 72:1108.
  102. Sweet SC. Update on pediatric lung allocation in the United States. Pediatr Transplant 2009; 13:808.
  103. Humar A, Fishman JA. Donor-derived infection: old problem, new solutions? Am J Transplant 2008; 8:1087.
  104. Kotton CN. Update on infectious diseases in pediatric solid organ transplantation. Curr Opin Organ Transplant 2008; 13:500.
  105. Bonde PN, Patel ND, Borja MC, et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant 2006; 25:99.
  106. Avlonitis VS, Krause A, Luzzi L, et al. Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur J Cardiothorac Surg 2003; 24:601.
  107. Shafer TJ, Davis KD, Holtzman SM, et al. Location of in-house organ procurement organization staff in level I trauma centers increases conversion of potential donors to actual donors. Transplantation 2003; 75:1330.
  108. Salim A, Brown C, Inaba K, et al. Improving consent rates for organ donation: the effect of an inhouse coordinator program. J Trauma 2007; 62:1411.
  109. Department of Health and Human Services, Health Resources and Services Administration: HRSA Transplant Center Growth and Management Collaborative: Best Practices Evaluation (September 2007). ftp://ftp. hrsa.gov/organdonor/transplantctrgrowth andmangmtcollaborbestpr acticesreport.pdf. (Accessed on November 26, 2013).
  110. Brown CV, Foulkrod KH, Dworaczyk S, et al. Barriers to obtaining family consent for potential organ donors. J Trauma 2010; 68:447.
  111. Boss R, Nelson J, Weissman D, et al. Integrating palliative care into the PICU: a report from the Improving Palliative Care in the ICU Advisory Board. Pediatr Crit Care Med 2014; 15:762.
  112. Lustbader D, O'Hara D, Wijdicks EF, et al. Second brain death examination may negatively affect organ donation. Neurology 2011; 76:119.